Brief: Adamis Receives FDA Approval For ZIMHI
18/10/2021 12:41
Oct 18 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS RECEIVES FDA APPROVAL FOR ZIMHI
* ADAMIS PHARMACEUTICALS - FDA HAS APPROVED ADAMIS' ZIMHI
(NALOXONE HCL INJECTION, USP) 5 MG/0.5 ML PRODUCT
Source text for Eikon: ID:nGNX38qBmB
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update